- Trial phase
- Filed/sNDA under FDA review (Phase 3 completed)
- Time to market
- If approved at the October 17, 2026 PDUFA date, commercial launch could follow within weeks (Ryzumvi is already manufactured and marketed for its approved indication).
- Why 5/10
- Next hard, dated catalyst is the PDUFA goal date of October 17, 2026 (~3.5 months away) for FDA decision on the supplemental NDA seeking to expand Ryzumvi's label to include presbyopia. This is a sNDA for an already-approved drug (Ryzumvi was approved Sept 2023 for reversing pupil dilation), so the binary risk is moderate. However, Viatris is a $14.3B-revenue diversified pharma (market cap ~$18-19B), so this label expansion, while meaningful, is not a make-or-break value driver for the stock.
Watch for the October 17, 2026 PDUFA decision on MR-141's presbyopia label expansion. Approval would add a differentiated non-pilocarpine presbyopia drop to Viatris's portfolio but faces crowded competition (Vuity, Qlosi, newly-approved Yuvezzi). For VTRS, this is a single positive catalyst in a broader turnaround story, not a stock-defining binary. The stock already rallied ~11% in 5 days on the sNDA acceptance news in Feb 2026.
Price Chart
Executive Summary
MR-141 is the same phentolamine ophthalmic solution 0.75% already marketed as Ryzumvi (FDA-approved September 2023 to reverse pharmacologically-induced pupil dilation after eye exams). Viatris is now seeking a label expansion to treat presbyopia, a large and growing market (~128 million Americans affected). Two positive Phase 3 trials support the application, with a PDUFA decision date of October 17, 2026. The drug has a differentiated mechanism (alpha-blocker) vs. existing presbyopia drops (which are mostly cholinergic agonists like pilocarpine). However, the presbyopia eye drop market is becoming crowded with competitors including Vuity (AbbVie/Allergan), Qlosi (Orasis), and newly-approved Yuvezzi (Tenpoint Therapeutics). For Viatris (a $14.3B-revenue global pharma company), this is a meaningful pipeline asset but represents a modest portion of total company value.
How It Works
Phentolamine is a non-selective alpha-1 and alpha-2 adrenergic antagonist, it blocks certain receptors in the iris dilator muscle, causing the pupil to constrict. This creates a "pinhole" effect that sharpens near vision, helping people with presbyopia (age-related inability to focus on close objects) see up close without reading glasses. It is a once-daily eye drop used in the evening.
Trial Status
Two pivotal Phase 3 trials (VEGA-2 and VEGA-3) completed. VEGA-3 (NCT06542497) enrolled 545 patients randomized 3:2 to MR-141 or placebo once daily in the evening. Positive top-line results announced June 26, 2025, met primary endpoint (≥3-line gain in binocular near visual acuity at 12 hours post-dose on day 8 and at 1 hour post-dose on day 1) and all secondary endpoints without compromising distance vision. sNDA accepted by FDA February 25, 2026. PDUFA goal date October 17, 2026.
The Two-Sided Case
Upcoming Catalysts
- October 17, 2026, PDUFA goal date for FDA decision on MR-141 sNDA for presbyopia
- Potential FDA Advisory Committee meeting (if convened) ahead of the PDUFA date
- Q2 and Q3 2026 earnings reports for Viatris (broader company context)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viatris Inc 8-K VTRS ·Originating report